| Dr Arshdeep Singh Sandhu, MD | |
|
44201 Dequindre Rd, Troy, MI 48085-1117 | |
| (248) 691-8646 | |
| Not Available |
| Full Name | Dr Arshdeep Singh Sandhu |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 11 Years |
| Location | 44201 Dequindre Rd, Troy, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730593146 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 4301111449 (Michigan) | Secondary |
| 207R00000X | Internal Medicine | 4301111449 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Spectrum Health | Grand rapids, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Spectrum Health Primary Care Partners | 4587568647 | 1585 |
News Archive
A University of Colorado Cancer Center study in this month's edition of the Journal of Investigative Dermatology describes a new target and potential treatment for melanoma, the most dangerous form of skin cancer. MicroRNA can decide which genes in a cell's DNA are expressed and which stay silent. Melanoma tends to lack microRNA-26a, which makes the gene SODD go silent.
A study involving a painful jaw disorder and the role of naturopathic medicine demonstrates how this holistic approach to care can empower patients to improve their own health.
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.
A new study has found that up to 20% of glioblastomas-an aggressive brain cancer-are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).
› Verified 1 days ago
| Entity Name | Spectrum Health Primary Care Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235188673 PECOS PAC ID: 4587568647 Enrollment ID: O20031121000091 |
News Archive
A University of Colorado Cancer Center study in this month's edition of the Journal of Investigative Dermatology describes a new target and potential treatment for melanoma, the most dangerous form of skin cancer. MicroRNA can decide which genes in a cell's DNA are expressed and which stay silent. Melanoma tends to lack microRNA-26a, which makes the gene SODD go silent.
A study involving a painful jaw disorder and the role of naturopathic medicine demonstrates how this holistic approach to care can empower patients to improve their own health.
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.
A new study has found that up to 20% of glioblastomas-an aggressive brain cancer-are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).
› Verified 1 days ago
| Entity Name | Mymichigan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740230127 PECOS PAC ID: 4981501939 Enrollment ID: O20040126000905 |
News Archive
A University of Colorado Cancer Center study in this month's edition of the Journal of Investigative Dermatology describes a new target and potential treatment for melanoma, the most dangerous form of skin cancer. MicroRNA can decide which genes in a cell's DNA are expressed and which stay silent. Melanoma tends to lack microRNA-26a, which makes the gene SODD go silent.
A study involving a painful jaw disorder and the role of naturopathic medicine demonstrates how this holistic approach to care can empower patients to improve their own health.
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.
A new study has found that up to 20% of glioblastomas-an aggressive brain cancer-are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).
› Verified 1 days ago
| Entity Name | Hospital Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073543013 PECOS PAC ID: 5991698185 Enrollment ID: O20040203000289 |
News Archive
A University of Colorado Cancer Center study in this month's edition of the Journal of Investigative Dermatology describes a new target and potential treatment for melanoma, the most dangerous form of skin cancer. MicroRNA can decide which genes in a cell's DNA are expressed and which stay silent. Melanoma tends to lack microRNA-26a, which makes the gene SODD go silent.
A study involving a painful jaw disorder and the role of naturopathic medicine demonstrates how this holistic approach to care can empower patients to improve their own health.
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.
A new study has found that up to 20% of glioblastomas-an aggressive brain cancer-are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Arshdeep Singh Sandhu, MD 44201 Dequindre Rd., Doctors Mailroom, Troy, MI 48085-1117 Ph: (248) 691-8646 | Dr Arshdeep Singh Sandhu, MD 44201 Dequindre Rd, Troy, MI 48085-1117 Ph: (248) 691-8646 |
News Archive
A University of Colorado Cancer Center study in this month's edition of the Journal of Investigative Dermatology describes a new target and potential treatment for melanoma, the most dangerous form of skin cancer. MicroRNA can decide which genes in a cell's DNA are expressed and which stay silent. Melanoma tends to lack microRNA-26a, which makes the gene SODD go silent.
A study involving a painful jaw disorder and the role of naturopathic medicine demonstrates how this holistic approach to care can empower patients to improve their own health.
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.
A new study has found that up to 20% of glioblastomas-an aggressive brain cancer-are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).
› Verified 1 days ago
Dr. Mehmet E Donat, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4600 Investment Dr, Ste 380, Troy, MI 48098 Phone: 248-267-5025 Fax: 248-267-5026 | |
Dr. Timothy J Tinetti, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4600 Investment Dr, Ste 300, Troy, MI 48098 Phone: 248-267-5000 Fax: 248-267-5001 | |
Dr. Sundeep S Dhillon, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4600 Investment Dr, Ste 290, Troy, MI 48098 Phone: 248-267-5010 Fax: 248-267-5011 | |
Dr. Jared Seth Bortman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 264 W Maple Rd, Suite 200, Troy, MI 48084 Phone: 248-273-9930 | |
Dr. Janet K Dubeck, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4600 Investment Dr, Ste 300, Troy, MI 48098 Phone: 248-267-5000 Fax: 248-267-5001 | |
Dr. Renato G Ramos, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1559 W Big Beaver Rd, Ste E, Troy, MI 48084 Phone: 248-649-0702 Fax: 248-649-9770 | |
Varinia Urday-gamalski, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 Kirts Blvd Ste 200, Troy, MI 48084 Phone: 800-759-7291 |